ArticleDiscover oncology2026

Tolerance and response of afatinib combined with tegafur in patients with advanced biliary tract cancer after failure of gemcitabine-based systemic therapy.

Zhizheng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.